Replies to post #356 on Alimera Sciences Inc (ALIM)

[Guynms26]

Wonder what caused ALIM's jump today? No news that I've heard that would cause it to jump 25%. I'm wondering if people are misreading the release about the resubmission of their drug to the FDA. They haven't approved ILUVIEN(R) yet. They only accepted the resubmission of it. Tomorrow should be interesting to see if it holds near $4 or drops back towards $3.

[pj McMulligan]

Any yall here short ALIM?

[surf1944]

2:02AM Alimera Sciences: UK's NICE issues final appraisal determination recommending ILUVIEN for chronic diabetic macular edema (ALIM) 3.76 : Co announcesthat in its Final Appraisal Determination, the United Kingdom's National Institute for Health and Care Excellence (NICE) has recommended ILUVIEN funding for the treatment of pseudophakic eyes in chronic diabetic macular edema patients that are insufficiently responsive to available therapies.

The final draft guidance reverses the published guidance issued by NICE on January 23, 2013, and takes into consideration a simple patient access scheme submitted by Alimera. In addition, NICE reviewed Alimera's updated data analysis showing ILUVIEN's cost effectiveness among a subgroup of chronic DME patients who have an eye that is considered pseudophakic, meaning that the eye has already undergone cataract surgery.

NICE's final guidance regarding reimbursement of ILUVIEN within the NHS in England and Wales is expected to be published in November 2013.

pSivida Corp (PSDV) is also associated with this decision.